Clinical Trial Update: Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

View source ↗

Summary

Clinical Trial Update discusses evaluating whether measurable residual disease (MRD) status predicts outcomes within a Phase III trial comparing fixed-duration …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Multiple Myeloma | Status: RECRUITING